EBCC, 21-23 March 2018, Barcelona
Welcome to Roche at EBCC 2018
The 11th European Breast Cancer Conference provided a multidisciplinary setting for breast cancer specialists from around the world. Attendees were able to expand their knowledge via a wide array of offerings such as symposia, workshops and special sessions on clinical cases.
EBCC 2018 – March 21-23, Barcelona
Discover Roche’s information from this year’s EBCC on this page, including two posters on breast cancer trials and a webcast of a symposium on HER2-positive eBC treatment.
Latest on Medically from EBCC 2018
EBCC 2018 poster: The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program
The UmbHER1 study assessed the safety and tolerability of subcutaneous (SC) Herceptin in patients with early (EBC) or metastatic breast cancer (MBC) treated with or without concurrent chemotherapy or pertuzumab. A pooled analysis of safety data from the 5 EBC and 2 MBC studies included in the UmbHER1 umbrella program is presented.
EBCC 2018 poster: Adjuvant pertuzumab for HER2-positive early stage breast cancer: a Swiss experience
In Switzerland, physicians can treat patients with unlicensed adjuvant pertuzumab through a special access mechanism by Swiss law (KVV71 a/b). This poster describes the experience of 12 patients treated with adjuvant pertuzumab, before the publication of APHINITY trial’s results, in the real-world setting in Switzerland. Patients treated with adjuvant pertuzumab between July 2015 and March 2017 at three Swiss cancer centers were identified.
EBCC 2018 Symposium - Navigating HER2-positive eBC treatment
Chapters I-IV: EBCC 2018 Symposium - What can we learn from clinical practice and trial data?
Navigating HER2-positive eBC treatment: What can we learn from clinical practice and trial data?' Chapter I/IV - Welcome
Watch Dr Baselga introduce the outline of the EBCC symposium. He will introduce the speakers and discuss general housekeeping.
Navigating HER2-positive eBC treatment: What can we learn from clinical practice and trial data?' Chapter II/IV - Where are we with the current HER2-positive eBC standard of care?
Dr Piccart-Gebhart covers the standard of care for HER2-positive eBC and how treatment options are evolving in this setting, including discussion of the APHINITY study. Treatment options for patients at low risk of recurrence are discussed in light of current treatment guidelines.
Navigating HER2-positive eBC treatment: What can we learn from clinical practice and trial data? Chapter III/IV - Which risk factors affect our treatment decisions, and how best to treat patients presenting them?
Dr Cortés focuses on adjuvant treatment options for patients with HER2-positive eBC at high risk of recurrence and outlines the importance of various risk factors for treatment decision making.
Navigating HER2-positive eBC treatment: What can we learn from clinical practice and trial data? Chapter IV/IV - Bridging neoadjuvant to adjuvant treatment
Dr Baselga discusses neoadjuvant treatment options, correlation of neoadjuvant treatment outcomes to long-term responses and optimal bridging to adjuvant treatment.